Biotechnology
Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST
Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?
Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.
Read
Commented by Stefan Feulner on September 13th, 2022 | 11:34 CEST
BioNTech, Cardiol Therapeutics, Bayer - Caution, turnaround!
The market correction due to geopolitical uncertainties and fears of further interest rate hikes mainly affected growth stocks in recent months, with the capital-intensive biotech sector losing disproportionately. However, the industry is growing dynamically and will become increasingly important in the coming years in the fields of application of the pharmaceutical and chemical industry, in the agricultural and food sector and in environmental protection. Due to the market correction, there are currently enormous opportunities for a turnaround in selected stocks.
Read
Commented by Fabian Lorenz on September 9th, 2022 | 10:53 CEST
300% chance with MorphoSys share? News from BioNTech and Defence Therapeutics
Analysts see a 300% price potential for MorphoSys. However, the latest quarterly figures did not give cause for euphoria. And not all analysts are so positive. On the other hand, BioNTech is currently doing well. The Mainz-based Company has received approval for its Omicron vaccine in the UK. However, the sustainable share price is increasingly determined by the pipeline. There is important news concerning the pipeline at Defence Therapeutics. In preclinical studies for the development of a novel cellular vaccine to fight cancer, the survival rate was 100%. The Canadians' unconventional approach could revolutionize modern medicine. More on the three biotech stocks here.
Read
Commented by Nico Popp on September 7th, 2022 | 12:18 CEST
Minimum risk, maximum opportunity: Thyssenkrupp, Saturn Oil + Gas, BioNTech
The energy price hammer, possible gas rationing in winter, and then there was the pandemic - but which issues end up impacting share prices? Are the risks around energy shortages already adequately priced into the industry? Are energy companies even fairly valued? And what opportunities can BioNTech still offer? We look at three stocks and provide an overview of opportunities and risks.
Read
Commented by Armin Schulz on September 5th, 2022 | 11:49 CEST
BioNTech, Cardiol Therapeutics, Formycon - Biotech stocks about to make a comeback?
Fears of a recession have recently pushed the markets down again. Those who want to bet on crisis-proof investments should look at biotech stocks. The world population is growing, people are getting older, and in line with age, more diseases are appearing. This trend will continue in the coming years. Therefore, the prospects for success in this sector are excellent. One cannot cut corners on health. Since September 2021, shares of biotech companies have also consolidated strongly. In some cases, shares appear severely undervalued. Today, we look at three interesting companies in the biotech sector.
Read
Commented by Nico Popp on September 1st, 2022 | 14:05 CEST
New trending stock in the wings? Plug Power, Cardiol Therapeutics, BioNTech
The markets want to go up! Last Friday, the Fed shock worried the markets, but today, even speculative stocks are picking up again. Especially stocks that were long considered deregistered can quickly develop potential. One example is Plug Power. Here, new demand in the wake of high energy prices meets good products. We explain the secret to the success of comeback stocks, using Plug Power as an example, and highlight new opportunities.
Read
Commented by Fabian Lorenz on August 31st, 2022 | 11:46 CEST
Poison pill slows down Nel share - will BioNTech and Almonty Industries soon take off?
The Nel ASA share is currently not for the faint-hearted. The stock is caught between hydrogen euphoria and a downward chart trend. Yet the news from the Company and the industry - such as the deal between Plug Power and Amazon - has been positive overall recently. But there is a poison pill. In contrast, the coming week could be exciting for BioNTech shareholders. In Germany, deliveries of the Corona vaccine, which has been adapted to virus variants, is scheduled to start. This could also give the shares of the German biotech flagship a new lease of life. The Almonty share could also soon break the knot. The discussion about reducing dependence on China for raw materials is picking up speed. Consistent with this, Almonty reports progress in the development of the tungsten mine in South Korea.
Read
Commented by André Will-Laudien on August 30th, 2022 | 12:35 CEST
Do not miss the turnaround: BioNTech, MorphoSys, Tocvan Ventures, TUI - shares on the move!
Making money on the stock market these days is not easy. Volatility is very high as the economy adjusts to entirely new conditions. Consumers have heavy loads to carry due to the energy crisis, and the still available household budgets are melting like ice in the sun in the face of inflation everywhere. Once again, fears are spreading that there might not be enough for a quiet retirement, and the savings rate is rising sharply. Those who remain active on the markets should proceed consistently according to analytical criteria because the dream of the eternal bull market is over for the time being. Here is a selection of good opportunities.
Read
Commented by Nico Popp on August 29th, 2022 | 12:25 CEST
Biotech stocks - The way it has to go! BioNTech, Defence Therapeutics, Bavarian Nordic
The pharmaceutical and biotech sectors are synonymous with a gold-rush atmosphere. As in the commodities sector, just one discovery can change everything for companies. The best example is BioNTech. Until the pandemic outbreak, the Company was, at best, a household name to biotech nerds. Today, the Palatinate-based company is on top and paying so many taxes that the treasurers of Mainz could pop the corks. We outline three biotech gems and do the future check. We start with BioNTech.
Read
Commented by Carsten Mainitz on August 24th, 2022 | 13:24 CEST
BYD, Meta Materials, Pfizer - Full pipeline
Uncertainty returns after the rises of recent weeks. In addition to equities, other asset classes such as precious metals and cryptocurrencies are also falling and marking a multi-week low. Besides the uncertain geopolitical situation, the culprit is mainly the fear of a global recession bundled with rampant inflation. It is challenging to currently filter out the right stocks from this overall negative environment. Nevertheless, many companies are shining with full order books and innovations and should benefit in the long term in the event of a turnaround.
Read